{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:10:17Z","timestamp":1761948617005,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11926-996-0039-x","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T13:52:17Z","timestamp":1180792337000},"page":"195-200","source":"Crossref","is-referenced-by-count":7,"title":["Outcome measures in psoriatic arthritis"],"prefix":"10.1007","volume":"7","author":[{"given":"Arthur","family":"Kavanaugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Cassell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"39_CR1","first-page":"290","volume":"19","author":"D Gladman","year":"1992","unstructured":"Gladman D, Espinoza L: International symposium on psoriatic arthritis. J Rheumatol 1992, 19:290\u2013291.","journal-title":"J Rheumatol"},{"key":"39_CR2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"N McHugh","year":"2003","unstructured":"McHugh N, Balachrishnan C, Jones S: Progression of peripheral joint disease in PsA; a 5 year prospective study. Rheumatology 2003, 42:778\u2013783. A carefully performed study that provides key information on prognostic factors for patients with PsA.","journal-title":"Rheumatology"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","volume":"41","author":"D Gladman","year":"1998","unstructured":"Gladman D, Farewell V, Wong K, et al.: Mortality studies in psoriatic arthritis; results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998, 41:1103\u20131110. A comprehensive analysis of a large clinic population of PsA.","journal-title":"Arthritis Rheum"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.61.4.298","volume":"61","author":"P Mease","year":"2002","unstructured":"Mease P: Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Annals Rheum Dis 2002, 61:298\u2013304.","journal-title":"Annals Rheum Dis"},{"issue":"Suppl 2","key":"39_CR5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1186\/ar1016","volume":"6","author":"A Gottlieb","year":"2004","unstructured":"Gottlieb A, Antoni C: Treating psoriatic arthritis: how effective are TNF antagonists. Arthritis Res Ther 2004, 6(Suppl 2):S31-S35.","journal-title":"Arthritis Res Ther"},{"key":"39_CR6","first-page":"126","volume":"2","author":"A Vaz","year":"2004","unstructured":"Vaz A, Barton J, Ritchlin C: Psoriatic arthritis: an update for clinicians. Int J Adv Rheumatol 2004, 2:126\u2013134. A recent review on psoriatic arthritis, with updates on important recent information, in particular as it relates to bone damage and its mechanisms.","journal-title":"Int J Adv Rheumatol"},{"key":"39_CR7","first-page":"62","volume":"17","author":"D Gladman","year":"1990","unstructured":"Gladman D, Farewell V, Buskila D, et al.: Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol 1990, 17:62\u201364.","journal-title":"J Rheumatol"},{"key":"39_CR8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.bor.0000129716.12154.06","volume":"16","author":"WJ Taylor","year":"2004","unstructured":"Taylor WJ: Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004, 16:350\u2013356. An excellent consideration of outcome measurements in PsA, with a focus on methods and validation.","journal-title":"Curr Opin Rheumatol"},{"key":"39_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/art.11417","volume":"50","author":"D Gladman","year":"2004","unstructured":"Gladman D, Helliwell P, Mease P, et al.: Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24\u201335. An excellent, thorough assessment of many varied outcome measurements in PsA, along with relevant historic considerations.","journal-title":"Arthritis Rheum"},{"key":"39_CR10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/art.1780370406","volume":"37","author":"H Fuchs","year":"1994","unstructured":"Fuchs H, Pincus T: Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994, 37:470\u2013475.","journal-title":"Arthritis Rheum"},{"key":"39_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"J Husted","year":"2001","unstructured":"Husted J, Gladman D, Farewell V, Cook R: Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:151\u2013158. An important paper that explores functional status and QOL in PsA patients.","journal-title":"Arthritis Rheum"},{"key":"39_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"J Fries","year":"1980","unstructured":"Fries J, Spitz P, Kraines R, et al.: Measurement of patient outcomes in arthritis. Arthritis Rheum 1980, 23:137\u2013145.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"39_CR13","first-page":"391","volume":"63","author":"P Mease","year":"2004","unstructured":"Mease P, Ganguly L, Wanke E, et al.: How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004, 63(Suppl 1):391.","journal-title":"Ann Rheum Dis"},{"key":"39_CR14","first-page":"1015","volume":"23","author":"J Husted","year":"1996","unstructured":"Husted J, Gladman D, Farewell V, et al.: Validation of the revised and expanded version of the arthritis impact measurement scales for patients with psoriatic arthritis. J Rheumatol 1996, 23:1015\u20131019.","journal-title":"J Rheumatol"},{"key":"39_CR15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"D Clegg","year":"1996","unstructured":"Clegg D, Reda D, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a department of Veterans Affairs cooperative study. Arthritis Rheum 1996, 39:2013\u20132020.","journal-title":"Arthritis Rheum"},{"key":"39_CR16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"D Felson","year":"1995","unstructured":"Felson D, Anderson J, Boers M, et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727\u2013735.","journal-title":"Arthritis Rheum"},{"key":"39_CR17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M","volume":"41","author":"D Felson","year":"1998","unstructured":"Felson D, Anderson J, Lange M, et al.: Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather then twenty percent? Arthritis Rheum 1998, 41:1564\u20131570.","journal-title":"Arthritis Rheum"},{"key":"39_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"A Gestel van","year":"1996","unstructured":"vanGestel A, Prevoo M, Hof M, et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis; comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism criteria. Arthritis Rheum 1996, 39:34\u201340.","journal-title":"Arthritis Rheum"},{"key":"39_CR19","first-page":"705","volume":"26","author":"A Gestel van","year":"1999","unstructured":"vanGestel A, Anderson J, van Riel P, et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999, 26:705\u2013711.","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"39_CR20","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2004.033894","volume":"64","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Krueger GG: Psoriatic Arthritis: Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA). Ann Rheum Dis 2005, 64(Suppl 2):ii1-ii2.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"39_CR21","doi-asserted-by":"crossref","first-page":"ii115","DOI":"10.1136\/ard.2004.032615","volume":"64","author":"D Gladman","year":"2005","unstructured":"Gladman D, Strand V, Mease P, et al.: OMERACT psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005, 64(Suppl 2):ii115-ii116.","journal-title":"Ann Rheum Dis"},{"key":"39_CR22","first-page":"2645","volume":"30","author":"W Taylor","year":"2003","unstructured":"Taylor W, Porter G, Helliwell P: Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis. J Rheumatol 2003, 30:2645\u20132658. A careful assessment of radiographic methods for PsA.","journal-title":"J Rheumatol"},{"key":"39_CR23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","volume":"37","author":"P Rahman","year":"1998","unstructured":"Rahman P, Gladman D, Cook R, et al.: Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998, 37:760\u2013765.","journal-title":"Br J Rheumatol"},{"key":"39_CR24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s003930170064","volume":"60","author":"S Wassenberg","year":"2001","unstructured":"Wassenberg S, Fischer O, Kahle V, et al.: A method to score radiographic changes in PsA. Z Rheumatol 2001, 60:156\u2013166.","journal-title":"Z Rheumatol"},{"key":"39_CR25","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P Mease","year":"2004","unstructured":"Mease P, Kivitz A, Burch F, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264\u20132272. A phase III study of etanercept in patients with PsA. This report provides key information on radiographic changes, along with detailed clinical responses to treatment with this tumor necrosis factor inhibitor.","journal-title":"Arthritis Rheum"},{"key":"39_CR26","first-page":"511","volume":"24","author":"J Husted","year":"1997","unstructured":"Husted J, Gladman D, Farewell V, et al.: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511\u2013517.","journal-title":"J Rheumatol"},{"key":"39_CR27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/ard.2003.006296","volume":"63","author":"A McKenna","year":"2004","unstructured":"McKenna A, Doward L, Whalley D, et al.: Development of the PsAQOL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004, 63:162\u2013169. A carefully performed assessment of QOL issues specific to patients with PsA.","journal-title":"Ann Rheum Dis"},{"key":"39_CR28","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C Antoni","year":"2005","unstructured":"Antoni C, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227\u20131236. A phase II study of infliximab in patients with PsA. This report provides information on dactylitis and enthesitis, along with detailed clinical responses to treatment with this tumor necrosis factor inhibitor.","journal-title":"Arthritis Rheum"},{"key":"39_CR29","doi-asserted-by":"crossref","unstructured":"Antoni C, Krueger G, de Vlam K, et al.: {btInfliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial}. Ann Rheum Dis 2005, In press. A phase III study of infliximab in patients with PsA. This report provides information on dactylitis and enthesitis, along with detailed clinical responses to treatment with this tumor necrosis factor inhibitor.","DOI":"10.1136\/ard.2004.032268"},{"key":"39_CR30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","volume":"62","author":"L Heuft-Dorenbosch","year":"2003","unstructured":"Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al.: Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003, 62:127\u2013132.","journal-title":"Ann Rheum Dis"},{"key":"39_CR31","first-page":"1003","volume":"26","author":"D Heijde van der","year":"1999","unstructured":"van derHeijde D, van der Linden S, Dougadas M, et al.: Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999, 26:1003\u20131005.","journal-title":"J Rheumatol"},{"key":"39_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","volume":"141","author":"D Ashcroft","year":"1999","unstructured":"Ashcroft D, Po A, Williams H, Griffiths C: Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of quality. Br J Dermatol 1999, 141:185\u2013191.","journal-title":"Br J Dermatol"},{"key":"39_CR33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/archderm.138.9.1221","volume":"138","author":"J Korte de","year":"2002","unstructured":"de Korte J, Mombers F, Sprangers M, Bos J: The suitability of quality-of-life measures for psoriasis research. Arch Dermatol 2002, 138:1221\u20131227. A systematic review of various instruments developed to assess QOL in psoriasis.","journal-title":"Arch Dermatol"},{"key":"39_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2133.2003.05378.x","volume":"149","author":"E Mazzotti","year":"2003","unstructured":"Mazzotti E, Picardi A, Sampogna F, et al.: Sensitivity of the Dermatology life quality index to clinical change in patients with psoriasis. Br J Dermatol 2003, 149:318\u2013322.","journal-title":"Br J Dermatol"},{"key":"39_CR35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","volume":"49","author":"P Rich","year":"2003","unstructured":"Rich P, Scher R: Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003, 49:206\u2013212. Development of a method to assess nail related changes in psoriasis.","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-996-0039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-996-0039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-996-0039-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T21:39:57Z","timestamp":1737063597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-996-0039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s11926-996-0039-x","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"type":"print","value":"1523-3774"},{"type":"electronic","value":"1534-6307"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}